Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05482789 · ClinicalTrials.gov registry record · Phase 4
Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes
A Phase 4 study of Gestational Diabetes, sponsored by Maisa N. Feghali, MD.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT05482789: Recruiting Phase 4 study of Gestational Diabetes, sponsored by Maisa N. Feghali, MD.
NCT05482789 is a Phase 4 study of Gestational Diabetes that is actively recruiting participants, run by Maisa N. Feghali, MD. The registered enrollment target is 13 participants, below the 322-participant average among 41 other Gestational Diabetes trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05482789, a Phase 4 study of Gestational Diabetes, is actively recruiting participants, sponsored by Maisa N. Feghali, MD.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to study how exenatide, an FDA-approved drug that lowers blood sugar in non-pregnant patients with type II diabetes, works in pregnant women. To do this, the investigators will study the drug's pharmacokinetics (what the body does to the drug; specifically, how quickly your body breaks down and excretes exenatide) and pharmacodynamics (what the drug does to the body; specifically, how effectively exenatide helps the participants' pancreas secrete insulin and how well it controls blood sugar after a meal). There are only two main drug therapies (insulin injections and glyburide pills) currently used for gestational diabetes and not all women achieve good enough blood sugar control without side effects. Therefore, the investigators hope to find out if exenatide might also be helpful in gestational diabetes.
Primary Outcome
Glucose concentration over the course of each study visit following mixed tolerance test
Conditions Studied
Interventions
- DRUG Exenatide
Study Locations (1)
Pennsylvania
- Magee Womens Hospital of UPMC - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2023-04-12 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 4 |
What NCT05482789 shows while recruiting
NCT05482789 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 322-participant average among 41 other Gestational Diabetes trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Gestational Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Exenatide is the first listed.
NCT05482789 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05482789 about?
NCT05482789 is a clinical study titled "Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes". This study is being done to study how exenatide, an FDA-approved drug that lowers blood sugar in non-pregnant patients with type II diabetes, works in pregnant women. To do this, the investigators will study the drug's pharmacokinetics (what the body does to the drug; specifically, how quickly your ...
What is the current status of trial NCT05482789?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 13 participants. The study started on 2023-04-12. Estimated completion is 2026-03-31.
What conditions does trial NCT05482789 study?
This clinical trial studies the following conditions: Gestational Diabetes.
What interventions are being tested in trial NCT05482789?
The interventions under investigation include: Exenatide (DRUG).
Who is sponsoring clinical trial NCT05482789?
This trial is sponsored by Maisa N. Feghali, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05482789 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gestational Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05482789's enrollment target sits among peer trials
13 41st of 41 higher than 1 of 41 other Gestational Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gestational Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
GDM: Insulin with or Without Metformin?
RECRUITING · Phase 4
-
Gestational Diabetes and Pharmacotherapy (GAP)
RECRUITING · Phase 4
-
Nutrition Optimization and Community Upliftment for Postpartum Recovery
RECRUITING · NA
-
Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2)
RECRUITING · NA
-
Delivering HOPE (Helping Women Optimize Prenatal Equity)
RECRUITING · NA
-
iGlucose® Remote Patient Monitoring Device as an Adjunct to Routine Glucose Meter Devices for Glycemic Management and Control in Gestational Diabetes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI